Understanding how a specific RNA affects liver cancer growth and immune response
Official title: Investigating the Immunosuppressive Function of lncRNA CRNDE in Hepatic Tumorigenesis
Funded at Tulane University of Louisiana · NIH-11127286 · Data updated 2026-11-12
This study is looking at a specific molecule called CRNDE in liver cancer to see how it affects immune cells that help fight tumors, with the goal of finding new ways to improve treatments for people with liver cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tulane University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project start | March 15, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $468,139 |
| NIH project number | 1R01CA291766-01A1 |
| Project ID | NIH-11127286 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with hepatocellular carcinoma who may benefit from enhanced immunotherapy treatments.
✕Less likely to help
Patients with liver cancer who do not have a compromised immune response or those with other types of cancer may not benefit from this research.
What this research studies
This research investigates the role of a long non-coding RNA (lncRNA) called CRNDE in liver cancer, specifically hepatocellular carcinoma (HCC). The study aims to understand how CRNDE contributes to the dysfunction of immune cells that typically fight tumors, which may lead to cancer progression. By examining the molecular mechanisms involved, the researchers hope to identify new therapeutic targets that could enhance the effectiveness of immunotherapy for HCC. The research will also test the effects of inhibiting CRNDE in mouse models to evaluate potential treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy options for patients with liver cancer, potentially enhancing their immune response against tumors.
How similar studies have gone: Previous research has shown promising results in targeting immune checkpoints in cancer, but the specific approach of targeting lncRNA CRNDE in HCC is relatively novel.
Where this research is happening
-
Tulane University of Louisiana
New Orleans, United States Active
Researchers
- Principal investigator: Zhang, Jinqiang — Tulane University of Louisiana
- Study coordinator: Zhang, Jinqiang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.